composition
Allogeneic peripheral blood progenitor cell transplantation (PBPCT) is increasingly being used instead of bone marrow transplantation (BMT) to reconstitute hematopoiesis after myeloablative chemoradiotherapy, 1 because it offers the advantage of high yields of hematopoietic precursor cells leading to accelerated hematopoietic recovery. Bone marrow and PBPC grafts not only differ in the frequencies of hematopoietic precursor cells but also contain different numbers and subsets of immunologically reactive cells. 2 Therefore, antitumor activity as well as graft-versus-host (GvH) reactivity may also be affected by the type of the transplant, as has been suggested by recent experimental 3 and clinical data. 4 Although granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage-colony stimulating factor (GM-CSF) are the only growth factors that have been used for the mobilization of allogeneic PBPCs in the clinic, 5 there are several other cytokines that can mobilize progenitor cells into the circulation. Besides hematopoietic growth factors like IL-3 6 and SCF, 7 mobilization of precursor cells has also been reported for flt3-ligand, 8 IL-11, 9 IL-6, 10 IL-7, 11 and other cytokines like IL-12 12 and CD40L, 13 primarily known for their effects on immune functions.
Since the antitumor effects of allogeneic stem cell transplantation mainly rely on the induction of immunologically mediated graft-versus-tumor activity, different strategies to exploit and enhance tumor-specific immune reactivity have been developed, most of them based on the selection of lymphoid subsets. 14 Since allogeneic transplantation of stem cells mobilized with G-CSF did not result in higher rates of acute graft-versus-host disease (GvHD) despite higher numbers of lymphocytes transplanted, 15 it has been proposed that immunologic functions are altered by G-CSF. [16] [17] [18] [19] [20] The use of different cytokines and combinations thereof to mobilize peripheral blood progenitor cells could represent a new approach to modify the immunological properties of the graft, which could be utilized alone or in association with more specific techniques for graft engineering to improve the clinical outcome of allogeneic transplantation.
Using an established preclinical model, 3, 21 we investigated the impact of SCF, given alone and in combination with G-CSF for progenitor cell mobilization, on graftversus-leukemia (GvL) and GVH reactivity after MHCidentical allogeneic PBPCT. Our data provide evidence for a role of different mobilization strategies to alter favorably the immunological properties of allogeneic stem cell grafts, which may help to control residual disease in patients with hematological malignancies. We demonstrate here a significant superiority of grafts from donors treated with G-CSF plus SCF when compared to G-CSF alone.
Materials and methods

Animals
Balb/c (H-2d), DBA (H-2d) and C57BL/6 (H-2b) mice were bred and kept at the animal facilities of the University of Kiel. All animals were housed in conventional cages, 7-10 animals to a cage, and were given nonsterilized food and water ad libitum. Cotrimoxazole was given for 40 days after PBPC transplantation.
Peripheral blood progenitor cell transplantation
Recipients (female Balb/c mice, 8-12 weeks of age) were injected with 1 Â 10 5 A20 leukemia cells 2 days prior to transplantation. They received a lethal dose of 7.5 Gy total body irradiation (TBI) 2 h before the transplant. Splenectomized donor mice (Balb/c or DBA, 10-16 weeks of age) were treated with optimal doses of recombinant human G-CSF (rhu-met-G-CSF at 250 mg/kg/day) or recombinant rat SCF (rrSCF at 100 mg/kg/day) alone or in combination for five consecutive days. Control animals received 1% human serum albumin (HSA) diluted in phosphate-buffered saline. Cytokines were kindly provided by Amgen (Thousand Oaks, CA, USA). Subcutaneous injection of cytokines was performed twice daily. The last injection was given 2 h before harvesting of PBPCs. Mice were then anticoagulated with heparine, anesthetized and killed by cervical dislocation. The peripheral blood was collected under sterile conditions by dissection of both carotid arteries. For each single experiment, the peripheral blood from two to four donors was pooled for each treatment group. Erythrocytes and debris were removed by density gradient centrifugation for 20 min at 1500g at room temperature (Lympholyte M, Cedarlane Laboratories Ltd, Hornby, Canada). The cell number was adjusted to 2 Â 10 7 nucleated cells (NC)/ml. NC/recipient (1 Â 10 7 ) were injected intravenously 2 h after irradiation of the recipients.
FACS analysis of PBPC grafts
The cellular composition of the grafts was investigated by flow cytometry carried out with a Becton Dickinson Facscan (San Jose, CA, USA). The following antibodies were used: 145-2C11 (CD3, Pharmingen, San Diego, CA, USA), RM4-4 (CD4, Pharmingen, San Diego, CA, USA), KT15 (CD8, Serotec, Wiesbaden, Germany), ID3 (CD19, Pharmingen, San Diego, CA, USA), PK-136 (NK-1.1, Dianova, Hamburg, Germany), RB6-8C5 (Gr-1, Pharmingen, San Diego, CA, USA), RAM34 (CD34, Pharmingen, San Diego, CA, USA). To assess changes in the expression of activation markers on NK-cells in PBPC-grafts, the number of NK-1.1-positive cells expressing the IL-2-Receptor beta chain and CD45R/B220 was determined by two-color flow cytometry with the following antibodies: TM-beta1 and RA3-6B2 (CD122 and CD45R/B220, Pharmingen, San Diego, CA, USA). NK-1.1-negative lymphocytes were analyzed for the expression of the IL-2-receptor alpha and beta chain with the antibodies 7D4 and TM-beta1 (CD25 and CD122, Pharmingen, San Diego, CA, USA).
Progenitor cell colony assays
CFU-GM and total CFCs were determined using the Methocult GF M3434 kit (Stemcell Technologies, Vancouver, Canada) according to the protocol of the manufacturer. CFUs were determined in sublethally (5 Gy) irradiated Balb/c mice 7 days after intravenous injection of 1 Â 10 5 NC from syngeneic donors.
Leukemia cells
A20 is a B-cell leukemia/lymphoma of Balb/c origin that occurred spontaneously in a 15-month-old mouse. 22 It is nonimmunogeneic in syngeneic hosts. A20 cells were continuously maintained in a culture medium consisting of RPMI 1640+5% FCS at 371C and 5% CO 2 . For use in transplantation experiments, leukemia cells were passaged in vivo.
Assessment of leukemia relapse, GvHD and graft rejection
All animals were examined daily and necropsied after death. Clinical signs of GvHD (weight loss, rough fur and gibbus) were documented. Peripheral blood counts were performed every 3 days from day 7 to full recovery of hematopoiesis or death. Death caused by leukemic relapse was defined as death with macroscopic evidence of tumor and liver weight 41.5 g (normal 1.370.2 g) and/or spleen weight 40.15 g (normal 0.170.02 g). Death caused by GvHD was defined as death with recovery of hematopoiesis (leukocytes 43/nl) and clinical signs of GvHD. In some animals with evident GvHD histologic examination of skin and liver was performed, which revealed changes compatible with acute GvHD. Death caused by graft failure/graft rejection was defined as death between days 6 and 30 after transplantation with a leukocytopenia o0.5/nl.
Assessment of long-term chimerism
In all surviving animals, long-term chimerism was investigated by flow cytometry determining the presence of the Lyt 1.1 antigen (CD5 MoAb, H11 86.1, Pharmingen, San Diego, CA, USA) on CD3-positive cells (Balb/c mice express the isoform Lyt 1.2, whereas DBA/2 mice are known to express Lyt 1.1). Untreated Balb/c animals served as negative controls. If the recipient mouse showed a fraction of 450% of CD3-positive cells being positive for Lyt1.1, it was considered to be a long-term chimera.
Statistical analysis
Survival and freedom from leukemia were calculated according to the method of Kaplan and Meier. The experimental groups were compared using the log-rank test. The calculations were carried out on a PC with 'Statistica' statistical software (StatSoft, Hamburg, Germany).
Results
Mobilization of hematopoietic progenitors using G-CSF and/or SCF
After s.c. injection of G-CSF at a dose of 2 Â 125 mg/kg/day for 5 days, the white blood cell count had increased by about six-fold ( Figure 1 ). In titration experiments (data not shown) 2 Â 50 mg/kg/day turned out to be the optimal dose of SCF for the mobilization of hematopoietic progenitor cells in DBA mice. While treatment with this dose of SCF alone doubled the peripheral blood cell count, a 10-fold increase in the number of NCs was observed after combining G-CSF with SCF. After 5 days of treatment, the median number of white blood cells had increased from 13.6 to 90.8/nl (G-CSF), 34.2/nl (SCF) and 120.4/nl (G-CSF+SCF).
Although the number of primitive hematopoietic progenitor cells, as determined by day 7 CFU-s assays, was highly variable in all treatment groups, a significantly increased number of spleen colony-forming cells was found to circulate in the blood of mice treated with G-CSF and SCF as compared to treatment with either growth factor ( Figure 2a ). Similar results were observed using short-term in vitro culture systems, which also indicated significantly increased numbers of colony-forming units (CFU-gm, Total-CFC; Figure 2b ) in mice receiving the combination treatment.
Cellular composition of the graft
Compared to peripheral blood progenitor cell grafts mobilized with G-CSF or G-CSF+SCF, grafts mobilized with SCF alone demonstrated an enhanced proportion of lymphocytes, especially CD3-positive T cells. Also, the relative number of CD19-positive B cells was slightly increased ( Figure 3 ). As expected, Gr-1-positive myeloid cells were the predominant cell population in the peripheral blood of animals treated with G-CSF alone. Although the relative proportion of lymphoid elements was reduced in these animals, the absolute number of T cells (CD3+/ml), B cells (CD19+/ml), and NK cells (5E6+/ml) was not affected by 5 days of treatment with G-CSF. In contrast, the absolute number of myeloid (Gr-1+) cells increased by more than 10-fold. Similar results were observed after treatment with G-CSF plus SCF. In comparison with bone marrow, all PBPC grafts contained a significantly increased proportion of CD3-positive T cells ( Figure 3) . However, the absolute numbers of T cells in G-CSF-mobilized grafts and grafts harvested after treatment with G-CSF plus SCF were identical (Table 1 ). The proportion of CD4-positive and CD8-positive subpopulations of T cells in the peripheral blood progenitor cell grafts mobilized by SCF, G-CSF or G-CSF+SCF was not altered compared to control animals ( Table 2) . Neither NK cells nor NK1.1-negative lymphocytes demonstrated any significant differences in the expression of activation markers (ie CD45R/B220 or the beta chain of the IL-2-receptor on NK cells and the alpha and beta chain of the IL-2-receptor on NK1.1-negative lymphocytes; data not shown).
Engraftment
Based on our previous experience with this model, 1 Â 10 7 of either marrow or peripheral blood cells were transplanted to reconstitute lethally irradiated Balb/c recipients. As shown in Figure 4 , no relevant differences in the kinetics of hematopoietic reconstitution were detected. All surviving animals proved to be long-term chimeras (data not shown).
Freedom from leukemia after transplantation of syngeneic grafts
After injection of 1 Â 10 5 leukemic cells, all untreated Balb/c mice died with a median survival time of 28 days. Mice receiving TBI followed by transplantation of syngeneic PBPC or bone marrow grafts showed a slightly prolonged median survival time, but only half of the animals remained tumor free at the end of the observation period (120 days after transplantation). No difference between bone marrow and PBPC grafts mobilized with different growth factors was detected in the syngeneic setting ( Figure 5 ).
GVL effects after transplantation of allogeneic BM and PBPC grafts
As previously reported, the transplantation of allogeneic MHC-identical bone marrow is not associated with a significant antileukemic effect in this experimental model. 3 After transfer of 1 Â 10 7 allogeneic bone marrow cells, leukemic relapse occurred in 60% of the animals ( Figure 6 ). This relapse rate was not significantly different from that seen after syngeneic BMT (55%, Figure 5 ). Even after addition of 5 Â 10 6 splenocytes (approximately 2.25 Â 10 6 CD3-positive T cells) to the bone marrow graft, the proportion of animals surviving free from leukemia was not significantly improved (60%, Table 1 ). In contrast to bone marrow transplants, PBPC grafts exerted relevant GvL activity in this model. 3 The transplantation of 1 Â 10 7 PBPCs mobilized with G-CSF alone (250 mg/kg for 5 days) resulted in an improved leukemiafree survival of 71%. The addition of SCF substantially enhanced the antileukemic activity of allogeneic grafts with Allo-PBPCs used to reconstitute hemotopoiesis G Hartung et al 94% of the recipients remaining free from leukemia (Po0.05, Figure 6 ). This result was reproduced in two independent sets of experiments.
The improved leukemia-free survival observed after transplantation of PBPCs mobilized with G-CSF plus SCF as opposed to the use of G-CSF-mobilized PBPCs cannot be explained by differences in the number or phenotype of T cells transferred with the grafts. Table 1 compares the absolute numbers of T-cell subsets in the collection product with the antileukemic effect observed after allogeneic transplantation. Nearly identical numbers of T cells were transferred with G-CSF-and G-CSF-plus SCF-mobilized grafts. The higher number of T cells transplanted with SCF-mobilized PBPCs did not translate into improved leukemia-free survival, thus further supporting the view that the observed differences in GvL activity are not simply related to the T-cell content of the graft. In an additional experiment, 5 Â 10 6 spleen cells were added to bone marrow grafts in order to achieve T-cell numbers comparable with those of PBPC grafts. Despite equivalent T-cell numbers, spleen-cell-enriched marrow grafts did not reach the antileukemic activity of growth-factor-mobilized grafts (Table 1) .
Mortality because of GVH disease after transplantation of allogeneic BM and PBPC grafts
The cumulative incidence of mortality because of GvHD was 50% in recipients of allogeneic G-CSF-mobilized PBPCs (Figure 7 ). Animals receiving transplants from donors treated with SCF or SCF plus G-CSF showed slightly lower rates of GVHD-related mortality. The incidence of lethal GvHD was lowest in recipients of allogeneic bone marrow grafts (22%) but this difference was not statistically significant. Since significant differences in the incidence of lethal GvHD after transplantation of PBPCs mobilized by G-CSF alone or G-CSF plus SCF were not observed, improved GVL activity of grafts harvested after treatment with both cytokines resulted in superior overall survival (40 vs 60%, P ¼ 0.06). tumor only, n=26
SCF, n=21 Figure 5 Freedom from leukemia after syngeneic transplantation. Balb/c mice were injected with 1 Â 10 5 cells of the B-lymphocytic leukemia cell line A20. Recipients received either no further treatment or received TBI with a dose of 7.5 Gy followed by transplantation of 1 Â 10 7 bone marrow or peripheral blood progenitor cells 2 days after leukemia cell injection. PBPCs were collected following treatment with rhu-met-G-CSF (250 mg/kg/ day for 5 days) and/or rr-SCF (100 mg/kg/day for 5 days). tumor only, n=26
SCF, n=22 Figure 6 Freedom from leukemia after allogeneic transplantation. Balb/c mice were injected with 1 Â 10 5 cells of the B-lymphocytic leukemia cell line A20. At 2 days after leukemia cell injection, recipients received either no further treatment or received TBI with a dose of 7.5 Gy followed by transplantation of 1 Â 10 7 bone marrow cells, 1 Â 10 7 bone marrow cells plus 5 Â 10 6 splenocytes or peripheral blood progenitor cells of MHCidentical DBA donors. PBPCs were collected following treatment with rhumet-G-CSF (250 mg/kg/day for 5 days) and/or rr-SCF (100 mg/kg/day for 5 days).
Discussion
Although a number of hematopoietic growth factors and combinations thereof have been used to mobilize autologous PBPCs, G-CSF and GM-CSF are still the only growth factors that have been administered to healthy donors of allogeneic grafts. Both in the autologous and the allogeneic setting, the engraftment of growth-factor-mobilized PBPC grafts has been extensively studied; however, little information is available describing and comparing the immunomodulatory properties of different PBPC harvest products.
We describe that the use of different hematopoietic growth factors in order to mobilize PBPCs may not only influence the incidence and speed of engraftment, but may also significantly change the immunotherapeutic potential of blood allografts. In particular, our data suggest that SCF, when used in combination with G-CSF for mobilization of allogeneic PBPC, not only improves the yield of hematopoietic progenitor cells but also results in enhanced antileukemic activity without a concomitant rise in GvHrelated mortality.
Previous studies have shown that peripheral blood from mice treated with G-CSF 23 or SCF 7 contains sufficient hematopoietic progenitor cells to reconstitute syngeneic recipients, 3, 21 and that allogeneic PBPCT can result in superior GvL activity compared to bone marrow grafts in these models. 3 SCF (the product of the Steel locus in the mouse) is a recently cloned hematopoietic growth factor primarily thought to induce the generation and proliferation of primitive hematopoietic progenitor cells. 24 It acts directly on hematopoietic stem cells to accelerate their entry into the cell cycle. 25 When used in combination with G-CSF, low doses of SCF enhanced the mobilization of PBPCs compared with G-CSF alone 26 and led to increased mobilization of cells with long-term engraftment potential. 27 Our findings are consistent with these observations (Figures 2a and b) with the exception that we did not observe a better recovery of platelets and WBCs posttransplant. This can be explained by the transfer of large progenitor cell numbers clearly above the threshold level where effects on the kinetics of hematopoietic recovery can be detected. 28 Clinical data also revealed increased mobilization of CFU-GM and CD34+ cells after treatment with SCF and G-CSF compared to G-CSF alone. 29, 30 While several studies have been performed to evaluate the hematopoietic properties of SCF-mobilized PBPCs in syngeneic transplantation models, 7, 31 we focused on immunological properties of allogeneic transplants generated with different mobilizing agents. Compared to bone marrow grafts, peripheral blood progenitor cell grafts contained about one log more T cells. Similar results were observed in humans. 32 With regard to the cellular composition of the peripheral blood progenitor cell grafts, our data indicate that treatment of splenectomized donors with SCF alone does not significantly affect the relative amount of most cell populations with the exception of slightly enhanced B-cell numbers. As expected, granulocytes became the predominant cell population in the peripheral blood of animals injected with G-CSF or the combination of G-CSF and SCF, whereas the absolute number of lymphocytes and lymphocyte subsets was not affected significantly. Ko¨rbling et al 33 reported similar results in humans after 3 days of treatment with G-CSF. Despite identical numbers of T-, B-, and NK cells in the G-CSF and G-CSF plus SCF groups, significant differences in the antileukemic effectiveness were found, that is, a significantly higher antileukemic activity of PBPCs mobilized with G-CSF and SCF compared to grafts mobilized with either factor alone ( Figure 6 ).
Several factors could be responsible for the differences in GvL activity of PBPC grafts obtained with different mobilization protocols. As a first possibility, a simple increase in the number of allogeneic T cells transferred to the host can be ruled out because recipients of grafts mobilized by G-CSF plus SCF and those of grafts mobilized by G-CSF alone received virtually identical numbers of CD4-and CD8-positive cells (Table 1) . Moreover, recipients of grafts mobilized with SCF alone, who received the largest number of T cells, did not show the lowest risk of leukemia relapse.
T cells, however, represent the most important effector cell population in our MHC-identical transplantation model 21 and differences in their activation, induced by the treatment with different growth factors, could play a major role in explaining the data reported. Pan et al 34 demonstrated that G-CSF can influence the polarization of CD4-positive cells in the Th2 direction, which may affect their GvH 34, 35 and GvL-activity. 36 Similar mechanisms could be responsible for the enhanced antileukemic activity of SCFtreated grafts. Bluman et al 37 found evidence that the vast majority of activated T cells express the c-kit mRNA transcript. Using allogeneic mixed lymphocyte assays, they also found evidence for a functional role of SCF in T-cell activation. In both CD8-and CD4-positive cells, the addition of SCF led to an increase in thymidine incorporation in a dose-dependent fashion. 37 However, a nonspecific activation of alloreactive T cells cannot explain why GvL activity is enhanced without a parallel increase in GvHrelated mortality. Since SCF plays a critical role in the early BM, n=15 G-CSF, n=26
SCF, n=22 Figure 7 Incidence of lethal GvHD after allogeneic transplantation. Balb/c mice received either no further treatment or received TBI with a dose of 7.5 Gy followed transplantation of 1 Â 10 7 bone marrow or peripheral blood progenitor cells of MHC-identical DBA donors. PBPCs were collected following treatment with rhu-met-G-CSF (250 mg/kg/day for 5 days) and/or rr-SCF (100 mg/kg/day for 5 days).
stages of T-lymphocyte development, 38 accelerated posttransplant T-cell recovery and maturation could also help to better control residual disease.
NK cells, another important cell type thought to play a role in the eradication of residual leukemia after allogeneic PBPCT, 39 can express receptors for SCF, 40 and in vitro data suggest that SCF influences NK-cell development and function. In vitro, human CD34-positive cells differentiate into NK cells in the presence of SCF plus IL-2, 41 and SCF improves the ability of CD56 bright NK cells to proliferate in response to IL-2. 40 However, exposure to SCF does not increase the cytotoxicity of CD56 bright cells against leukemia target cells in vitro nor does it augment IL-2-induced LAK activity. On the other hand, some data suggest that NK activity is impaired and NK-cell progenitors are diminished in G-CSF-mobilized human PBPC grafts. 16, 42 In our model, we found no evidence for an altered recruitment of NK cells into the blood of donors treated with SCF plus G-CSF in comparison with those treated with G-CSF alone. Moreover, neither the expression of activation markers like B220 nor of the beta chain of the IL-2-receptor on NK cells was significantly altered by treatment with G-CSF or SCF.
There are other candidate cell populations that could influence the GvL activity of PBPC grafts. Although there is no well-established role of mast cells in the context of tumor and alloreactivity, it cannot definitely be excluded that this cell type could mediate antileukemia responses. SCF has been shown to promote the proliferation and maturation of mast cells in vitro and can increase the number of tissue mast cells by greater than 100-fold, 43 while a polarization towards a Th2 immune response results in a downregulation of mast cell effector proteins. 44 In murine mast cells, SCF provokes the release of Il-6 and TNF-a. 45 Another cell population with potent immunostimulatory features are antigen-presenting cells (APCs). In humans, G-CSF mobilizes Th2-inducing dendritic cells 18, 19 and results in impaired production of IL-12.
46 SCF shows only limited direct effects on the formation of dendritic cells, but by cytokine release of other cell populations it may influence APC function indirectly.
Clinically, SCF has been reported to be relatively well tolerated up to doses of 10 mg/kg. Although the combination of G-CSF and SCF can improve the yield of apheresis products, its use in the allogeneic setting seems limited by the side effects because of SCF-induced mast cell proliferation and degranulation. On the other hand, family members might be willing to accept more side effects if the graft would carry a significantly better GvL activity.
Although our data should be interpreted with caution before the results have been evaluated in other experimental systems, we believe that our findings are important, since they may be regarded as a proof of principle. They for the first time demonstrate that the utilization of different hematopoietic growth factors not only results in the modification of the kinetics of hematopoietic reconstitution but may also change important immunological functions of allografts. In order to maximize immunologically mediated antitumor activity, the use of different cytokines and mobilization techniques should be further investigated with regard to their effects on GvH and GvL activity. Optimal strategies for the mobilization of stem cells and GvL effector cells may ultimately help to produce allogeneic stem cell grafts with more potent antileukemic activity but less GvHD-inducing potential.
